Synovus Financial’s Sarepta Therapeutics SRPT Stock Holding History

Synovus Financial’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-7,000	Closed	-$685K	–	2082
2020 Q1	$685K	Buy	+7,000	New	+$800K	0.01%	440

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Synovus Financial's SRPT Position: Q3 2020 in Review

Synovus Financial sold out of Sarepta Therapeutics (SRPT) in Q3 2020, closing a stake of 56 shares — an estimated $9K sold.

Synovus Financial first reported a position in SRPT in Q2 2013 and held it in 10 quarters. The position peaked at $24K in Q3 2013. 403 funds tracked by Wall St. Rank hold SRPT as of Q3 2020.

Synovus Financial reported no remaining Sarepta Therapeutics position as of Q3 2020 after selling out during the quarter.
Synovus Financial sold 56 Sarepta Therapeutics shares in Q3 2020, an estimated $9K.
Synovus Financial first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 10 quarters.
Synovus Financial's Sarepta Therapeutics position peaked at $24K in Q3 2013.
403 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2020.

Based on Synovus Financial's 13F filing for Q3 2020, filed 9 Nov 2020.